Search Results 1021-1030 of 18397 for Immunode

1. A Study Of Tolododekin Alfa (ANK-101) In Combination With An Anti-PD-1/PD-L1 Antibody In Participants With Advanced Non-Small Cell Lung Cancer - Mayo Clinic

   Human immunodeficiency virus (HIV)-infected participants must be on anti-retroviral therapy (ART) and have well-controlled HIV infection/disease. Resolution ...

2. Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   History of active primary immunodeficiency; Known history of previous tuberculosis; Active infection including hepatitis B, hepatitis C or human ...

3. A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens - Mayo Clinic

   Known history of positive test for human immunodeficiency (HIV) or known acquired immunodeficiency syndrome (AIDS) Complete inclusion and exclusion criteria are ...

4. Anaplastic large cell lymphoma - Symptoms and causes - Mayo Clinic

   Infection with human immunodeficiency virus (HIV). People with HIV have weakened immune systems. That increases the risk of ALK-negative ALCL. Ongoing ...

5. An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies - Mayo Clinic

   History of human immunodeficiency virus infection. Untreated brain or CNS metastases or brain/CNS metastases that have progressed (eg, evidence of new or ...

6. Phase ll Study of Pirfenidone in Patients With RAILD - Mayo Clinic

   Medical history including Human Immunodeficiency Virus (HIV);; Medical history of viral hepatitis (positive Hep A antibody in the absence of elevated liver ...

7. Kay L. Medina, Ph.D. - Mayo Clinic Faculty Profiles

   ... immunodeficiency well documented in patients with chronic lymphocytic leukemia (CLL). Dr. Medina's lab recently showed that patients with CLL have impaired ...

8. A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - Mayo Clinic

   * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART). Exclusion Criteria: The main ...

9. A Global Phase III Study Of Rilvegostomig Or Pembrolizumab Plus Chemotherapy For First-Line Treatment Of Metastatic Non-squamous NSCLC - Mayo Clinic

   * Active primary immunodeficiency/active infectious disease(s). * Active tuberculosis infection. Participating Mayo Clinic locations. Study statuses change ...

10. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

    Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable or unquantifiable viral load within 6 months ...